Asieris unveils positive results for Phase III trial of APL-1702

30 September 2024

China-based Asieris Pharmaceuticals (SH: 688176) announced that the international multicenter Phase III clinical study data of its non-surgical treatment for cervical high-grade squamous intraepithelial lesion (HSIL) product Cevira (APL-1702) will be published at the 27th Chinese Society of Clinical Oncology (CSCO) as a poster, focusing on the analysis of different age subgroups regarding the six-month pathological regression rate and HPV clearance rate.

The candidate is partnered with Norwegian bladder cancer company, Photocure (OSE: PHO), whose shares rose almost 5% to 55.20 kroner on the news, while Asieris jumped 13.4% to 6.59 renminbi.

This study is a prospective, randomized, double blind, placebo controlled, multicenter Phase III clinical study, which has reached its primary efficacy endpoint and exhibited good safety.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK